Macrogenics (FRA:M55) Total Debt per Share: €0.48 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:M55 Macrogenics Inc FRA:M55
50 GF Score
Price €3.54
GF Value €3.37
! 5 Warning Signs
View Full Analysis

What is Macrogenics Total Debt per Share?

Macrogenics FRA:M55 +1.14% 50 Total Debt per Share is €0.48 as of Jun. 2026. GuruFocus rates FRA:M55 with a GF Score™ of 50/100 and a GF Value™ of €3.37. The stock has 5 warning signs investors should review.

€0.48 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Macrogenics's Total Debt Per Share for the quarter that ended in Jun. 2026 was €0.48.

Macrogenics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Macrogenics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macrogenics Total Debt per Share Chart

Macrogenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.53 0.50 0.57 0.50

Macrogenics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.50 0.50 0.50 0.48
FRA:M55
50GF Score
Macrogenics Inc FRA:M55
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macrogenics Total Debt per Share Calculation

Macrogenics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(27.0+4.4)/63.3
=0.50

Macrogenics's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(26.1+4.3)/63.6
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of €0.48 mean?
Macrogenics (FRA:M55) has a Total Debt per Share of €0.48 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Macrogenics and its competitors.
Is Macrogenics' Total Debt per Share too high?
Macrogenics' current Total Debt per Share is €0.48. Overall, Macrogenics has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Total Debt per Share compare to RNAC and CNXU?
Macrogenics' Total Debt per Share of €0.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Macrogenics and its competitors. Macrogenics's current Total Debt per Share is €0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Macrogenics (FRA:M55) has a current Total Debt per Share of €0.48. The stock's GF Value™ is €3.37, compared to a current price of €3.54 — trading 5% above its estimated fair value. The current Total Debt per Share is €0.48. Macrogenics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Total Debt per Share is €0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €3.54 is trading 5% above its estimated GF Value™ of €3.37.

Key valuation signals for FRA:M55:

  • Total Debt per Share: €0.48
  • GF Value™: €3.37 vs. price of €3.54 (5% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
50GF Score

Get the complete analysis for FRA:M55

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.54
Price
€3.37
GF Value